These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15638051)

  • 21. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure.
    Krintel SB; Grunert VP; Hetland ML; Johansen JS; Rothfuss M; Palermo G; Essioux L; Klause U
    Rheumatology (Oxford); 2013 Jul; 52(7):1245-53. PubMed ID: 23459699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of efficacy and safety of multiple intravenous infusion of anti-tumor necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis].
    Wiland P; Głowska A; Chlebicki A; Szechiński J
    Pol Arch Med Wewn; 2002 Nov; 108(5):1055-63. PubMed ID: 12685246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
    Visvanathan S; Wagner C; Smolen J; St Clair EW; Hegedus R; Baker D; Keenan G
    Arthritis Rheum; 2006 Sep; 54(9):2840-4. PubMed ID: 16948115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Furst D; Weisman MH; St Clair EW; Keenan GF; van der Heijde D; Marsters PA; Lipsky PE;
    Arthritis Rheum; 2004 Apr; 50(4):1051-65. PubMed ID: 15077287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
    Cavazzana I; Bobbio-Pallavicini F; Franceschini F; Bazzani C; Ceribelli A; Bravi E; Zingarelli S; Caporali R; Cattaneo R; Montecucco CM
    Clin Exp Rheumatol; 2007; 25(5):676-83. PubMed ID: 18078613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide.
    Bingham SJ; Buch MH; Kerr MA; Emery P; Valadäo Barcelos AT
    Arthritis Rheum; 2004 Dec; 50(12):4072-3. PubMed ID: 15593202
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.
    Favalli EG; Sinigaglia L; Varenna M; Arnoldi C
    Lupus; 2002; 11(11):753-5. PubMed ID: 12475006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis.
    Marchesoni A; Sarzi Puttini P; Gorla R; Caporali R; Arnoldi C; Atzeni F; Vianelli M; Pallavicini FB
    Clin Exp Rheumatol; 2005; 23(6):916-7. PubMed ID: 16396721
    [No Abstract]   [Full Text] [Related]  

  • 31. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
    Kapetanovic MC; Larsson L; Truedsson L; Sturfelt G; Saxne T; Geborek P
    Arthritis Res Ther; 2006; 8(4):R131. PubMed ID: 16869978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center Cohort.
    Ishikawa Y; Fujii T; Ishikawa SK; Yukawa N; Hashimoto M; Furu M; Ito H; Ohmura K; Mimori T
    PLoS One; 2016; 11(9):e0162896. PubMed ID: 27643491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease.
    Elezoglou A; Kafasi N; Kaklamanis PH; Theodossiadis PG; Kapsimali V; Choremi E; Vaiopoulos G; Sfikakis PP
    Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S65-9. PubMed ID: 17949554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab-induced autoantibodies: a multicenter study.
    Vaz JL; Fernandes V; Nogueira F; Arnóbio A; Levy RA
    Clin Rheumatol; 2016 Feb; 35(2):325-32. PubMed ID: 26676808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
    Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
    Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.
    Pascual-Salcedo D; Plasencia C; Ramiro S; Nuño L; Bonilla G; Nagore D; Ruiz Del Agua A; Martínez A; Aarden L; Martín-Mola E; Balsa A
    Rheumatology (Oxford); 2011 Aug; 50(8):1445-52. PubMed ID: 21427177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept.
    Aghdashi MA; Khadir M; Dinparasti-Saleh R
    Curr Rheumatol Rev; 2020; 16(1):61-66. PubMed ID: 31057111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
    Haraoui B; Cameron L; Ouellet M; White B
    J Rheumatol; 2006 Jan; 33(1):31-6. PubMed ID: 16395747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The early clinical course of infliximab treatment in rheumatoid arthritis: results from the REMARK observational study.
    Westhovens R; van Vollenhoven RF; Boumpas DT; Brzosko M; Svensson K; Bjorneboe O; Meeuwisse CM; Srinivasan S; Gaudin P; Smolen JS; Rahman MU; Nelissen RL; Vastesaeger N
    Clin Exp Rheumatol; 2014; 32(3):315-23. PubMed ID: 24529163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
    Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
    J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.